Tara Gomes1, Andrea Mastorakos1, J Michael Paterson1, Ingrid Sketris1, Patricia Caetano1, Simon Greaves1, David Henry1. 1. Affiliations: Li Ka Shing Knowledge Institute of St. Michael's Hospital (Gomes); Institute for Clinical Evaluative Sciences (Gomes, Paterson, Greaves, Henry); Institute of Health Policy, Management, and Evaluation (Gomes, Paterson, Henry), University of Toronto; Leslie Dan Faculty of Pharmacy (Gomes), University of Toronto; Faculty of Arts and Sciences (Mastorakos), University of Toronto, Toronto, Ont.; Department of Family Medicine (Paterson), McMaster University, Hamilton, Ont.; College of Pharmacy (Sketris), Dalhousie University, Halifax, NS; Faculty of Health Sciences (Caetano), University of Manitoba; Provincial Drug Programs (Caetano), Government of Manitoba, Winnipeg, Man.; Centre for Research in Evidence-Based Practice (Henry), Bond University, Gold Coast, Australia.
Abstract
BACKGROUND: In February 2012, a reformulated tamper-deterrent form of long-acting oxycodone, OxyNeo, was introduced in Canada. We investigated the impact of the introduction of OxyNeo on patterns of opioid prescribing. METHODS: We conducted population-based, cross-sectional analyses of opioid dispensing in Canada between 2008 and 2016. We estimated monthly community pharmacy dispensing of oral formulations of codeine, morphine, hydromorphone and oxycodone, and a transdermal formulation of fentanyl, and converted quantities to milligrams of morphine equivalents (MMEs) per 1000 population. We used time series analysis to evaluate the effect of the introduction of OxyNeo on these trends. RESULTS: National dispensing of long-acting opioids fell by 14.9% between February 2012 and April 2016, from 36 098 MMEs to 30 716 MMEs per 1000 population (p < 0.01). This effect varied across Canada and was largest in Ontario (reduction of 22.8%) (p = 0.01) and British Columbia (reduction of 30.0%) (p = 0.01). The national rate of oxycodone dispensing fell by 46.4% after the introduction of OxyNeo (p < 0.001); this was partially offset by an increase of 47.8% in hydromorphone dispensing (p < 0.001). Although dispensing of immediate-release opioids was a substantial contributor to overall population opioid exposure across Canada, it was unaffected by the introduction of OxyNeo (p > 0.05 in all provinces). INTERPRETATION: The findings suggest that the introduction of a tamper-deterrent formulation of long-acting oxycodone in Canada, against a background of changing public drug benefits, was associated with sustained changes in selection of long-acting opioids but only small changes in the quantity of long-acting opioids dispensed. This illustrates the limited effect a tamper-deterrent formulation and associated coverage policy can have when other, non-tamper-deterrent alternatives are readily available. Copyright 2017, Joule Inc. or its licensors.
BACKGROUND: In February 2012, a reformulated tamper-deterrent form of long-acting oxycodone, OxyNeo, was introduced in Canada. We investigated the impact of the introduction of OxyNeo on patterns of opioid prescribing. METHODS: We conducted population-based, cross-sectional analyses of opioid dispensing in Canada between 2008 and 2016. We estimated monthly community pharmacy dispensing of oral formulations of codeine, morphine, hydromorphone and oxycodone, and a transdermal formulation of fentanyl, and converted quantities to milligrams of morphine equivalents (MMEs) per 1000 population. We used time series analysis to evaluate the effect of the introduction of OxyNeo on these trends. RESULTS: National dispensing of long-acting opioids fell by 14.9% between February 2012 and April 2016, from 36 098 MMEs to 30 716 MMEs per 1000 population (p < 0.01). This effect varied across Canada and was largest in Ontario (reduction of 22.8%) (p = 0.01) and British Columbia (reduction of 30.0%) (p = 0.01). The national rate of oxycodone dispensing fell by 46.4% after the introduction of OxyNeo (p < 0.001); this was partially offset by an increase of 47.8% in hydromorphone dispensing (p < 0.001). Although dispensing of immediate-release opioids was a substantial contributor to overall population opioid exposure across Canada, it was unaffected by the introduction of OxyNeo (p > 0.05 in all provinces). INTERPRETATION: The findings suggest that the introduction of a tamper-deterrent formulation of long-acting oxycodone in Canada, against a background of changing public drug benefits, was associated with sustained changes in selection of long-acting opioids but only small changes in the quantity of long-acting opioids dispensed. This illustrates the limited effect a tamper-deterrent formulation and associated coverage policy can have when other, non-tamper-deterrent alternatives are readily available. Copyright 2017, Joule Inc. or its licensors.
Authors: Irfan A Dhalla; Muhammad M Mamdani; Marco L A Sivilotti; Alex Kopp; Omar Qureshi; David N Juurlink Journal: CMAJ Date: 2009-12-07 Impact factor: 8.262
Authors: Tara Gomes; Muhammad M Mamdani; J Michael Paterson; Irfan A Dhalla; David N Juurlink Journal: Can Fam Physician Date: 2014-09 Impact factor: 3.275
Authors: Marie-Josephine Seya; Susanne F A M Gelders; Obianuju Uzoma Achara; Barbara Milani; Willem Karel Scholten Journal: J Pain Palliat Care Pharmacother Date: 2011
Authors: Tara Gomes; Muhammad M Mamdani; Irfan A Dhalla; Stephen Cornish; J Michael Paterson; David N Juurlink Journal: Addiction Date: 2014-07-07 Impact factor: 6.526
Authors: Andrea Iaboni; Michael A Campitelli; Susan E Bronskill; Christina Diong; Matthew Kumar; Laura C Maclagan; Tara Gomes; Mina Tadrous; Colleen J Maxwell Journal: CMAJ Open Date: 2019-09-23
Authors: Charlotte G Boone; Tony Antoniou; David N Juurlink; Teagan Rolf von den Baumen; Sophie A Kitchen; Georgia C Richards; Mina Tadrous; Tara Gomes Journal: CMAJ Open Date: 2021-12-14
Authors: Brent D Ershoff; Tristan Grogan; Joe C Hong; Pamela A Chia; Eilon Gabel; Maxime Cannesson Journal: Anesthesiology Date: 2020-05 Impact factor: 7.892